Ropes & Gray advised MOMA Therapeutics on the deal. MOMA Therapeutics announced a collaboration and licensing agreement with Swiss pharmaceutical leader Roche (SIX: RO, ROG; OTCQX: RHHBY)....
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Accutar Biotechnology on the transaction. Accutar Biotechnology announced a partnership with Evommune focused on the discovery of novel small molecule drug candidates in...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the deal. Novo Nordisk A/S and Valo Health, Inc. announced they have entered into an agreement to discover and...
You must be a Standard 1 Year member to access this content.
Ropes & Gray acted as legal advisor to TransMedics, and Cooley acted as legal advisor to Bridge to Life. TransMedics Group, Inc. (Nasdaq: TMDX) announced that is...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised uniQure N.V. on the deal. uniQure N.V. signed an agreement to sell a portion of the royalty rights due to uniQure from biopharmaceutical...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen, while Walder Wyss advised the funds managed by Pharmakon Advisors. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into a term loan...
You must be a Standard 1 Year member to access this content.
Greenberg Traurig represented Huadong Medicine on the deal, while Ropes & Gray advised Kiniksa Pharmaceuticals. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of...
You must be a Standard 1 Year member to access this content.
Cravath and Lenz & Staehelin represented Taro in connection with the transaction. Ropes & Gray advised Galderma. Taro Pharmaceutical Industries Ltd. (“Taro”), a multinational, science-based pharmaceutical...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Blueprint Medicines in the deal. Blueprint Medicines annunced an exclusive collaboration and licensing agreement with Zai Lab Limited for the development and...
You must be a Standard 1 Year member to access this content.
Zhong Lun and Ropes & Gray advised LianBio on the deal. LianBio executed an initial public offering and listing of American depositary shares on the Nasdaq...
You must be a Standard 1 Year member to access this content.
